Sodium-glucose co-transporter-2 (SGLT-2) inhibitors were developed for their effects on blood glucose, and large-scale trials mandated by the US FDA were initiated to assess their cardiovascular safety in populations with type 2 diabetes mellitus (DM) at high atherosclerotic cardiovascular (ASCVD) risk [1]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.